Genetic susceptibility to Barrett’s oesophagus: Lessons from early studies

John M Findlay1,2,3, Mark R Middleton3 and Ian Tomlinson1,3

Abstract
Barrett’s oesophagus (BO) is a common condition, predisposing strongly to the development of oesophageal adenocarcinoma (OAC). Consequently, there has been considerable effort to determine the processes involved in the development of BO metaplasia, and ultimately develop markers of patients at risk. Whilst a number of robust acquired risk factors have been identified, a genetic component to these and the apparent increased susceptibility of certain individuals has long been suspected. This has been evidenced in part by linkage studies, but subsequently two recent genome-wide association studies (GWAS) have suggested mechanisms underlying the heritability of BO, as well as providing the first direct evidence at modern levels of statistical significance. This review discusses BO heritability, in addition to that of individual variants and genes reported to be associated with BO to date. Through this, we identify a number of plausible associations, although often tempered by issues of methodology, and discuss the priorities and need for future research.

Keywords
Barrett’s oesophagus, oesophageal adenocarcinoma, genetics, biomarkers, genetic susceptibility

Introduction
Barrett’s, or columnar-lined, oesophagus (BO) is a common premalignant condition, conferring a considerable risk of progression to oesophageal adenocarcinoma (OAC). As both conditions become more common, the need for a better understanding of both becomes yet more pressing.1 At a translatable level, recent advances in high-throughput techniques have reinforced the potential for genomic biomarkers to help stratify susceptibility risk, and identify novel pathways, processes and therapeutic targets. This review summarises the results to date of genetic studies of BO, discusses the lessons learnt and suggests priorities for future research.

Epidemiology
BO is the replacement of normal oesophageal squamous epithelium with macroscopically visible columnar epithelium, with or without demonstration of intestinal metaplasia.2,3 Adult prevalence of BO in the Western world is 0.5%–2.0%.4,5 Whilst associated with both frequency and duration of gastrooesophageal reflux disease (GORD) symptoms, many patients are asymptomatic and this relationship may be deceptive,6 corresponding with evidence that endoscopy-negative GORD, reflux oesophagitis and BO may in some regards be distinct processes.7 Additional risk factors include male gender, Caucasian ethnicity, increasing age, obesity, smoking, and a positive family history.8

Barrett’s inheritance
The pathophysiology of GORD is extremely complicated, representing interactions between intrinsic oesophageal physiological factors (such as dysmotility),
anatomical variants (such as hiatus hernia) and environmental risk factors. It is likely that the first two are modified by genetic variants, and in the case of BO, variants may also modulate the propensity to develop metaplasia after reflux, by mechanisms such as antioxidant imbalance and cytokine profiles.

Although most BO cases appear sporadic, evidence for genetic predisposition is provided by studies identifying clustering of cases within families. However, whilst such ‘familial’ BO has been reported in up to 20% of first- or second-degree relatives, and an autosomal-dominant mode of inheritance with incomplete penetrance proposed, it is unlikely that this level of risk is representative of sporadic BO. How much phenotypic variation is accounted for by genetic factors is unclear. Traditionally, estimates of disease-associated variance have been made by concordance studies, ideally of twins. One such study estimated 43% of the GORD phenotype to be heritable, although no studies have been performed for BO.

However, early experiences with genome wide association studies (GWAS) have provided a novel perspective on heritability. These use the principle of linkage disequilibrium blocks (the non-random association of alleles at two or more loci) to genotype thousands of cases and controls using large single nucleotide polymorphism (SNP) arrays. GWAS suggest that most disease-associated variants exert a weak effect (typically an odds ratio (OR) <1.5 per allele) and are common (present in >5% of individuals). This underpins the ‘common disease-common variant’ (CDCV) model, which suggests that the majority of trait-associated variation occurs at highly polymorphic and conserved loci. These variants demonstrate low penetrance individually, but multiple variants and permutations combine to influence risk. However, although for some common diseases tens of loci have been identified, cumulatively these explain only a minority of heritability. The location and nature of this missing heritability is unclear; however, candidates include rare variants (by definition omitted from arrays) of moderate effect, undiscovered common variants of still weaker effect, variants not ‘tagged’ on existing arrays, epigenetics and inflated heritability estimates.

Two GWAS of BO have been performed, by the Wellcome Trust Case Control consortium (WTCCC) reporting initially in 2012, with further analysis in 2015, and the Barrett’s and Esophageal Adenocarcinoma CONsortium (BEACON) in 2013. Using linear mixed models of all SNPs in the BEACON genome-wide data, Ek et al. estimated heritability to be 35%, overlapping extensively with OAC. The WTCC GWAS found that more than 1000 variants contribute to BO phenotype by means of concordance of SNPs between unrelated individuals, and a disease score analysis. Subsequently, an estimate of 9.9% was made, considerably lower than the BEACON estimate. Future GWAS and complementary studies will undoubtedly refine these estimates, but the genetic contribution to BO susceptibility appears substantial.

Candidate genes studies of susceptibility

At present, clinical factors are insufficient to guide selective screening for BO. However, reliable genomic biomarkers might facilitate this. Such markers include SNPs, short insertion or deletions, tandem repeat sequences and copy number variants. Prior to GWAS, the identification of such markers necessitated either a candidate gene or linkage-based approach to gene identification.

Plausible candidates are suggested by the genes involved in metaplasia, and a number of statistically significant associations (p < 0.05) have been reported (Table 1). However, extensive heterogeneity of association study methodology and quality limit their generalisability. Whilst approximately half of studies have used power calculations (although for effect sizes exceeding those predicted by the CDCV model), most studies have used low numbers of cases and controls, often representing opportunistic analysis of tissue not prospectively archived. Another frequent issue is multiple comparisons; studies often compare numerous genotype and haplotype permutations, but for half the associations reported it is not clear that their reported statistical significance would withstand correction for this multiple testing. Relatively few studies have used multivariate analysis to assess independence from clinical risk factors and other variants. There have also been differences as to cases-control matching, and defining controls. These reported associations must therefore be considered within this context, and with the majority assessed by only one study many may represent publication bias. Ultimately, no associations have been validated by independent studies, although one – the rs1695 A to G missense variant (Ile105Val) in glutathione s-transferase P (GSTP) – is supported by meta-analysis.

GSTP1 is a phase II enzyme involved in the handling of endotoxins. The common rs1695 A>G missense variant results in substitution of valine for isoleucine leading to reduced activity. It has been assessed by four studies, one demonstrating a statistically significant association, albeit derived from only 22 cases. In 2009, Bull et al. calculated a pooled OR for BO of 1.50 (95% confidence interval (CI) 1.16–1.95). Another assessed endotoxin-handling variant is the A>G substitution rs785049 in the pregnant X receptor (PXR); however, as the p value was not reported, and no corrections were made for multiple comparisons, it is unclear whether this association was genuine.
| Variant | Gene | Association | Wild-type | Effect variant | Ethnicity |
|---------|------|-------------|-----------|----------------|-----------|
| rs9257809 | MHC region | Su et al. 2012 | A | Caucasian |
| rs9936833 | FOXF1 | Levine et al. 2013 | A | Caucasian |
| rs10419226 | CRTC1 | Associated with either BO/OAC | G | Caucasian |
| rs11789015 | BARX1 | Associated with BO when combined with Su et al. 2012 | T | Caucasian |
| rs2687201 | FOXP1 | Palles et al. 2015 | G | Caucasian |
| rs3072 | GDF7 | Palles et al. 2015 | G | Caucasian |
| rs2771108 | TBX5 | Palles et al. 2015 | G | Caucasian |
| Genome-wide association studies | Candidate studies | Homeotic regulators | Ren et al. 2014 | AA | Caucasian |
| rs2237091 | CDX1 | Ren et al. 2014 | AA | Caucasian |
| rs717746 | CDX1 | Ren et al. 2014 | GG | Caucasian |
| rs3776083 | CDX1 | Ren et al. 2014 | AG | Caucasian |
| rs4769585 | CDX2 | Ren et al. 2014 | CT | Caucasian |
| rs3812863 | CDX2 | Ren et al. 2014 | AG | Caucasian |
| rs3776082 | CDX1 | Ren et al. 2014 | AA | Caucasian |
| Inflammatory mediators | | IL1B | Izakovicoka-Holla et al. 2013 | T | Caucasian |
| rs1143634 | IL1RN | Izakovicoka-Holla et al. 2013 | 1/2 | Caucasian |
| VNTR polymorphism | | IL1B/ILRN | Izakovicoka-Holla et al. 2013 | C/T/C/long | Caucasian |
| rs1800587/rs16944/ | IL1B/ILRN | Izakovicoka-Holla et al. 2013 | C/T/C/long | Caucasian |
| rs1143634/IL1RN | IL1B/ILRN | Izakovicoka-Holla et al. 2013 | T/C/C/long | Caucasian |
| rs909253 | TNFB | Menke et al. 2012a | AA | Caucasian |
| rs917897 | IL18RAP | Babar 2012 et al. | CC | Caucasian |
| rs1946518 | IL18 | Babar et al. 2012 | CC | Caucasian |
| rs11209026 | IL23R | Gaj et al. 2008 | A | Caucasians |
| rs32112227 | IL12B | Moons et al. 2008 | C | Caucasian |
| rs415958/rs16944 | IL1RA/IL1B | Gough et al. 2005 | CC/A | NS (UK) |
| rs1800896 | IL10 | Gough et al. 2005 | CC | NS (UK) |
| Growth factors | | EGF | Menke et al. 2012b | GG | Caucasian |
| rs4444903 | IGF1 | McElholm et al. 2010 | AA | Caucasian |
| rs6214 | IGF1 | MacDonald et al. 2009 | A | Caucasian |
| rs2229765 + BMI > 30 | IGF1R | MacDonald et al. 2009 | A | Caucasian |
The caudal homeobox (CDX) homeotic regulators 1 and 2 have been implicated as promoters of metaplasia, and are up-regulated by exposure of oesophageal squamous epithelium to bile acids. Ten SNPs in either CDX1 or CDX2 were tested by Ren et al. in 2014, following correction for multiple comparisons, three CDX1 (unadjusted) associations were reported (rs3776082 GG, rs2237091 AA and rs717767 GG variant genotypes). However, whilst associations with age, gender and hiatus hernia were demonstrated, multivariate analysis was not performed for these. Additionally, these SNPs are non-coding, and so any mechanisms of effect are not immediately apparent.

Reflux-induced inflammation is integral to BO. Numerous cytokine pathway variants have been tested, but whilst associations have been reported for variants in the IL1 cluster, none would appear to remain significant following adjustment for multiple comparisons, other than the wild-type rs917997 variant in IL18RAP and rs3212227 A>C SNP in IL12B, both adjusted for clinical risk factors.

Another group of candidate genes are the growth factors, heavily implicated in the metaplasia-dysplasia-adenocarcinoma sequence; similarly, just three (adjusted for clinical covariates) would appear to survive multiple comparisons: rs6214 G>A in IGF1, rs2229765 G>A in IGFIR, and rs444903 in EGF. Other variants include rs9344 G>A in the cell cycle regulator CCND1, resulting in bypass by DNA-damaged cells of the G1/S phase checkpoint. An association of wild-type rs25487 G>A in the nucleotide excision repair component XRCC1 with BO was also demonstrated by the same authors, although not supported by Ferguson et al. in a larger study. However, the involvement of cell cycle and DNA damage regulators highlights the accumulation of somatic variation and genomic instability characterising BO clonal populations.

A recent model-free linkage analysis of 21 sibling pairs with either BO or OAC also searched for new candidate genes, by definition representing rarer but high penetrance alleles, associated with ‘familial’ rather than ‘sporadic’ BO. This identified three: MSR1, ASCC1, and CTHRC1. Prospective evaluation reported an association with rs41341748 (MSR1) with a combination of BO/OAC, although no assessment was made for BO alone. This variant is thought to disrupt the function of the class A macrophage scavenger receptor encoded by MSR1, with consequent effects on oxidative stress, inflammation and apoptosis. Due to the complexity involved in BO pathogenesis, it is likely that analogous variants are yet to be identified.

However, despite the apparent plausibility a priori of many of these variants, this must be tempered by the absence of validation, methodology quality and small

### Table 1. Continued.

| Variant | Gene | Association | Ethnity | Wild-type Effect | Variant Wild-type Effect |
|---------|------|-------------|---------|-----------------|-------------------------|
| rs6785049 | PXR | van de Winkel et al.29 2011 | G | Caucasian |
| rs1695 | GSTP | van de Winkel et al.29 2009 | G | Caucasian |
| rs9344 | CCND1 | Casson et al.31 2005a | AA | NS (Caucasian) |
| rs25487 | XRCC1 | Casson et al.31 2005b | AA | NS (Caucasian) |
| rs2305764 | MyoPb | Menke et al.32 2012c | GG | Caucasian |
| rs2305764 | MyoPb | Menke et al.32 2012c | GG | Caucasian |
| rs1799750 | MMP1 | Bradbury et al.32 2009 | GG | Caucasian |
| rs1800566 | NQO1 | di Martino et al.33 2007 | T | NS (UK) |

NS: not specified; BO: Barrett’s oesophagus; OAC: oesophageal adenocarcinoma; MHC: major histocompatibility complex; VNTR: variable number of tandem repeat; BMI: body mass index; UK: unknown.
GWAS

In contrast to candidate studies, GWAS are large, laborious and expensive, but have a number of scientific advantages. Their hypothesis-free approach allows detection of variants in unsuspected genes or regulatory loci, ancestry can be derived and used as a covariate, and pathway enrichment analysis may implicate previously unsuspected processes. As introduced above, their principle rests on linkage disequilibrium; SNPs tend to associate with each other, with each estimated in our dataset: On meta-analysis the rs2687201 association with BO one, rs3784262 (BARX1) and rs10419226 (CRTC1).18 None reached the genome-wide threshold for BO alone, although rs10419226 reached 5.54 × 10⁻⁸. BARX1 encodes a transcription factor involved in oesophageal and pulmonary embryogenesis,50 BARX1 similarly contributes to trachea-oesophageal embryogenesis via the Wnt pathway;51 CRTC1 is a transcriptional co-activator, although its role is unclear.

We subsequently assessed these SNPs using the WTCC discovery dataset: On meta-analysis the rs2687201 association reached genome-wide significance for BO alone, that of rs11789015 improved (non-significantly), but that of rs10419226 reduced (with no association evident in our dataset). In addition, we assessed 87 SNPs with possible evidence of association (p < 1 × 10⁻⁸) in the BEACON GWAS: Whilst none demonstrated a significant association with BO one, rs3784262 (ALDH1A2), demonstrated an association with BO/OAC: 0.90 (0.87–0.93; p = 3.72 × 10⁻⁵).

Pathway analysis

Another advantage of GWAS is the facilitation of pathway or gene set enrichment analysis (GSEA). This helps identify contributory biological pathways, elucidating pathogenesis, and suggesting clues to diagnostic and therapeutic targets, and somewhat mitigating the limitations of considering genes in isolation. These include the risk that stringent correction for multiple testing may obscure genuine associations; furthermore, genes and variants function not in isolation, but within a constellation of others.

GSEA takes a priori-defined gene sets, and determines whether variants in these are randomly distributed across significance levels, or in fact deviate (as would be
the case if the set contributed to the phenotype). GSEA platforms calculate an enrichment score, for gene sets and subsequently false discovery rate (FDR). We recently performed GSEA of the WTCCC GWAS data using two platforms. Whilst no pathways with FDR<0.05 were identified by both, three were associated with FDR<0.05 by one with supportive evidence by the other (FDR<0.25): the Kyoto Encyclopedia of Genes and Genomes (KEGG) type 1 diabetes mellitus, antigen processing and presentation and autoimmune thyroid disease pathways, supporting the roles of the inflammatory response in BO pathogenesis.

Next-generation sequencing

In contrast to genotyping variants at specific base positions, DNA sequencing determines the complete sequence of nucleotides. First-generation (Sanger) sequencing was described in 1977, determining the sequence base by base. Second- (or next-) generation sequencing (NGS) techniques use massively parallel sequencing processes to sequence the exome, genome or transcriptome (messenger RNA, mRNA). Sequenced fragments are mapped, variants identified and their functional significance predicted. A handful of NGS studies have been performed in oesophageal cancer, although focussing on somatic variants. One study identified candidate driver mutations present in OAC and adjacent BO, but no dedicated BO studies have been performed. As with GWAS cost is often prohibitive, but it is likely that as techniques are refined (including single molecule sequencing), they will identify new candidates and pathways for validation and functional annotation.

Conclusion

To date, a variety of approaches, from small-scale candidate studies of solitary variants, to large-scale GWAS of many thousands of cases and controls, have advanced our understanding of the complex heritability and pathogenesis of BO. Furthermore, they have provided us with a number of plausible candidate genomic biomarkers of susceptibility. However, other than a small number of GWAS-identified variants, none is supported by sufficient quality and quantity of evidence. A concerted approach, of both complementary GWAS and rigorous candidate validations (perhaps within the robust framework afforded by multicentre clinical trials), is required to better evaluate and identify genomic biomarkers within the context of established clinical markers. From a translatabile biological perspective, these associations point strongly to the role of both inflammation and development in BO. The former process in particular is amenable to intervention, as underpinning the ongoing Phase III Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia (AspECT) in patients with established BO. However, ultimately future studies may support the role of similar chemoprevention in selected patients prior to the development of BO.

Funding

Core funding is provided to the Wellcome Trust Centre for Human Genetics from the Wellcome Trust (090532/Z/09/Z).

Conflict of interest

None declared.

References

1. van Soest EM, Dieleman JP, Siersema PD, et al. Increasing incidence of Barrett’s oesophagus in the general population. Gut 2005; 54: 1062–1066.
2. Watson A, Heading RC and Shepherd NA. The definition of “Barrett’s” columnar-lined oesophagus. In: Guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus. UK: British Society of Gastroenterology, 2005.
3. Conio M, Cameron AJ, Chak A, et al. Endoscopic treatment of high-grade dysplasia and early cancer in Barrett’s oesophagus. Lancet Oncol 2005; 6: 311–321.
4. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C & M criteria. Gastroenterology 2006; 131: 1392–1399.
5. Cameron AJ. Barrett’s esophagus and adenocarcinoma: From the family to the gene. Gastroenterology 1992; 102: 1421–1424.
6. Eisen GM, Sandler RS, Murray S, et al. The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus. Am J Gastroenterol 1997; 92: 27–31.
7. Findlay JM and Maynard ND. Pathophysiology and investigation of gastro-oesophageal reflux disease. In: Griffin SM, Raimes SA and Shenfine J (eds) Oesophagogastric surgery, 5th ed. Philadelphia, USA: Saunders/Elsevier, 2013.
8. Smith KJ, O’Brien SM, Smithers BM, et al. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 2005; 14: 2481–2486.
9. Fitzgerald RC, Abdalla S, Onwuegbusi BA, et al. Inflammatory gradient in Barrett’s oesophagus: Implications for disease complications. Gut 2002; 51: 316–322.
10. Drozdlic CM, Goddard KA, Chak A, et al. Demographic and phenotypic features of 70 families segregating Barrett’s oesophagus and oesophageal adenocarcinoma. J Med Genet 2003; 40: 651–656.
11. Mohammed I, Cherkas LF, Riley SA, et al. Genetic influences in gastro-oesophageal reflux disease: A twin study. Gut 2003; 52: 1085–1089.
12. Manolio TA, Brooks LD and Collins FS. A HapMap harvest of insights into the genetics of common disease. *J Clin Invest* 2008; 118: 1590–1605.

13. Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A* 2009; 106: 9362–9367.

14. Reich DE and Lander ES. On the allelic spectrum of human disease. *Trends Genet* 2001; 17: 502–510.

15. Visscher PM. Sizing up human height variation. *Nat Genet* 2008; 40: 489–490.

16. Su Z, Gay LJ, Strange A, et al. Common variants at the *TBX5* and *GDF7* are associated with increased risk for Barrett’s esophagus. *Gastroenterology* 2015; 148: 367–378.

17. Palles C, Chegwidden L, Li X, et al. Polymorphisms near *TBX5* are associated with a variant of *IL23R* associates with a variant of *IL-1* gene cluster are associated with *TBX5* and *GDF7* are associated with increased risk for Barrett’s esophagus. *Hum Immunol* 2013; 74: 1161–1169.

18. Levine DM, Ek WE, Zhang R, et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. *Nat Genet* 2013; 45: 1487–1493.

19. Ek WE, Levine DM, D’Amato M, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett’s esophagus, and gastroesophageal reflux. *J Natl Cancer Inst* 2013; 105: 1711–1718.

20. Ren D, Zheng G, Bream S, et al. Single nucleotide polymorphisms of caudal type homeobox 1 and 2 are associated with Barrett’s esophagus. *Dig Dis Sci* 2014; 59: 57–63.

21. Izakovicova Holla L, Borilova Linhartova P, Hrdlickova B, et al. Haplotypes of the IL-1 gene cluster are associated with gastroesophageal reflux disease and Barrett’s esophagus. *Hum Immunol* 2013; 74: 1161–1169.

22. Menke V, Pot RG, Moons LM, et al. Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett’s esophagus and esophageal adenocarcinoma. *J Hum Genet* 2012; 57: 26–32.

23. Babar M, Ryan AW, Anderson LA, et al. Genes of the interleukin-18 pathway are associated with susceptibility to Barrett’s esophagus and esophageal adenocarcinoma. *Am J Gastroenterol* 2012; 107: 1331–1341.

24. Gaj P, Mikula M, Wyrwicz LS, et al. Barrett’s esophagus associates with a variant of *IL23R* gene. *Acta Biochim Pol* 2008; 55: 365–369.

25. Moons LM, Kusters JG, van Delft JH, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. *Carcinogenesis* 2008; 29: 926–931.

26. Gough MD, Ackroyd R, Majeed AW, et al. Prediction of malignant potential in reflux disease: Are cytokine polymorphisms important? *Am J Gastroenterol* 2005; 100: 1012–1018.

27. McElholm AR, McKnight AJ, Patterson CC, et al. A population-based study of IGF axis polymorphisms and the esophageal inflammation, metaplasia, adenocarcinoma sequence. *Gastroenterology* 2010; 139: 204–12.e3.

28. MacDonald K, Porter GA, Guernsey DL, et al. A polymorphic variant of the insulin-like growth factor type I receptor gene modifies risk of obesity for esophageal adenocarcinoma. *Cancer Epidemiol* 2009; 33: 37–40.

29. Bull, et al. Phase I and II enzyme polymorphisms as risk factors for Barrett’s esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis. *Dis Esophagus* 2009; 22(7): 571–587.

30. Kala Z, Dolina J, Marek F, et al. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett’s esophagus. *J Hum Genet* 2007; 52: 527–534.

31. Casson AG, Zheng Z, Evans SC, et al. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. *Carcinogenesis* 2005; 26: 1536–1541.

32. Bradbury PA, Zhai R, Hopkins J, et al. Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. *Carcinogenesis* 2009; 30: 793–798.

33. di Martino E, Hardie LJ and Wild CP. The NAD(P)H:quinone oxidoreductase I C609T polymorphism modifies the risk of Barrett esophagus and esophageal adenocarcinoma. *Genetics in Medicine* 2007; 9(6): 341–347.

34. Murphy SJ, Hughes AE, Patterson CC, et al. A population-based association study of SNPs of GSTP1, MnSOD, GPX2 and Barrett’s esophagus and esophageal adenocarcinoma. *Carcinogenesis* 2007; 28: 1323–1328.

35. Casson AG, Zheng Z, Porter GA, et al. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. *Cancer Detect Prev* 2006; 30: 423–431.

36. van Lieshout EM, Tiemessen DM, Witteman BJ, et al. Low glutathione and glutathione S-transferase levels in Barrett’s esophagus as compared to normal esophageal epithelium. *Jpn J Cancer Res* 1999; 90: 81–85.

37. Wong NA, Wilding J, Bartlett S, et al. *CDX1* is an important molecular mediator of Barrett’s metaplasia. *Proc Natl Acad Sci U S A* 2005; 102: 7565–7570.

38. Betticher DC, Thachter N, Altermatt HJ, et al. Alternate splicing produces a novel cyclin D1 transcript. *Oncogene* 1995; 11: 1005–1011.

39. Ferguson HR, Wild CP, Anderson LA, et al. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett’s esophagus, or esophageal adenocarcinoma: Results from the factors influencing the Barrett’s adenocarcinoma relationship case-control study. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 736–739.

40. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. *Cancer Res* 2004; 64: 7629–7633.

41. Orloff M, Peterson C, He X, et al. Germline mutations in *MSR1*, *ASCC1*, and *CTHRC1* in patients with Barrett esophagus and esophageal adenocarcinoma. *JAMA* 2011; 306: 410–419.

42. Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. *Nature* 2001; 411: 199–204.
43. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature* 2010; 467: 832–838.

44. Dura P, van Veen EM, Salomon J, et al. Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. *Int J Cancer* 2013; 133: 1751–1755.

45. Mahlapuu M, Enerbäck S and Carlsson P. Haploinsufficiency of the forkhead gene Foxf1, a target for sonic hedgehog signaling, causes lung and foregut malformations. *Development* 2001; 128: 2397–2406.

46. Castillo D, Puig S, Iglesias M, et al. Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett’s esophagus. *J Gastrointest Surg* 2012; 16: 227–237; discussion 237.

47. Rallis C, Bruneau BG, Del Buono J, et al. Tbx5 is required for forelimb bud formation and continued outgrowth. *Development* 2003; 130: 2741–2751.

48. Shu W, Lu MM, Zhang Y, et al. Foxp2 and Foxp1 cooperatively regulate lung and esophagus development. *Development* 2007; 134: 1991–2000.

49. Woo J, Miletich I, Kim BM, et al. Barx1-mediated inhibition of Wnt signaling in the mouse thoracic foregut controls tracheo-esophageal septation and epithelial differentiation. *PloS One* 2011; 6: e22493.

50. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005; 102: 15545–15550.

51. Sanger F, Nicklen S and Coulson AR. DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* 1977; 74: 5463–5467.

52. Grada A and Weinbrecht K. Next-generation sequencing: Methodology and application. *J Invest Dermatol* 2013; 133: e11.

53. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. *Nat Methods* 2010; 7: 248–249.

54. Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. *Cancer Discov* 2012; 2: 899–905.

55. Schadt EE, Turner S and Kasarskis A. A window into third-generation sequencing. *Hum Mol Genet* 2010; 19: R227–R240.